34 results on '"Mottolese, Marcella"'
Search Results
2. The use of a panel of monoclonal antibodies can lower false-negative diagnoses of peritoneal washing in ovarian tumors
- Author
-
Mottolese, Marcella, Salzano, Marco, Vincenzoni, Cristina, Benevolo, Maria, Bigotti, Aldo, Iacovelli, Annunziaia, Lombardi, Antonio, Atlante, Giuseppe, and Natali, Pier Giorgio
- Subjects
Ovarian cancer -- Metastasis ,Monoclonal antibodies ,Ovarian cancer -- Diagnosis ,Metastasis -- Diagnosis ,Health - Abstract
The examination of peritoneal washings is an important part of both the initial staging and follow-up of ovarian cancer. If cancerous cells have begun to spread from the ovary, they may be detected by rinsing the abdominal cavity and examining the fluid. In cases where there is no cancer spread large enough to be visible to the surgeon, these washings may provide the only indication that the cancer is advancing. Likewise, in the follow-up of patients who have already been treated for ovarian cancer, the presence of cancer cells in fluid rinsed from the abdominal cavity may provide the first indication of recurrence. The examination of the rinsing fluids is not straightforward, however. Normal cells will be recovered with this method, and even with careful examination cancerous cells may not be detected among the normal cells. A study was conducted to determine if monoclonal antibodies may be used to improve the examination of such washings. Monoclonal antibodies are highly specific and may be used to immunocytochemically stain cancer cells; the cells stained in this manner would then stand out noticeably against the background of normal cells, which stain little or not at all. Four different monoclonal antibodies were tested in the evaluation of 117 patients who were undergoing surgery for ovarian abnormalities and 121 patients who were undergoing a 'second-look' operation to observe for signs of recurrent cancer. The fluid used to rinse the abdomen was examined in the conventional way, and the cells were also stained with the monoclonal antibodies. For the patients undergoing their first surgical procedure, the traditional technique identified cancerous cells in 11 of 27 cases involving early cancer and 21 of 30 cases of advanced cancer. The antibodies, on the other hand, detected cancerous cells in the rinsing fluid in 15 of 27 early cancer cases and in 25 of 30 cases of advanced cancer. Similarly, for the patients being followed-up, traditional examination revealed cancerous cells in 39 of 121 cases while the antibodies revealed cancerous cells in 61 of 121 cases. These results indicate that the use of monoclonal antibodies to stain cells in fluid rinsed from the abdomen can increase the chances for the detection of ovarian cancer cells. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
3. Low frequency of ErB-2 proto-oncogene overexpression in human leukocyte antigen-A2-positive breast cancer patients
- Author
-
Nistico, Paola, Mottolese, Marcella, Mammi, Caterina, Benevolo, Maria, Del Bello, Duilia, Rubiu, Oriana, Gentile, Francesco Paolo, Botti, Claudio, Venturo, Irene, and Natali, Pier Giorgio
- Subjects
Proto-oncogenes ,Breast cancer -- Diagnosis ,Health - Published
- 1997
4. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis
- Author
-
Di Modugno, Francesca, Spada, Sheila, Palermo, Belinda, Visca, Paolo, Iapicca, Pierluigi, Di Carlo, Anna, Antoniani, Barbara, Sperduti, Isabella, Di Benedetto, Anna, Terrenato, Irene, Mottolese, Marcella, Gandolfi, Francesco, Facciolo, Francesco, Chen, Emily, Schwartz, Martin, Santoni, Angela, Bissell, Mina, and Nisticò, Paola
- Abstract
We demonstrated previously that the splicing of the actin regulator, hMENA, generates two alternatively expressed isoforms, hMENA11aand hMENAΔv6, which have opposite functions in cell invasiveness. Their mechanisms of action have remained unclear. Here we report two major findings: (i) hMENA regulates β1 integrin expression. This was shown by depleting total hMENA, which led to loss of nuclear expression of serum response factor (SRF)-coactivator myocardin-related transcription factor 1 (MRTF-A), leading to an increase in the G-actin/F-actin ratio crucial for MRTF-A localization. This in turn inhibited SRF activity and the expression of its target gene β1 integrin. (ii) hMENA11areduces and hMENAΔv6 increases β1 integrin activation and signaling. Moreover, exogenous expression of hMENA11ain hMENAΔv6-positive cancer cells dramatically reduces secretion of extracellular matrix (ECM) components, including β1 integrin ligands and metalloproteinases. On the other hand, overexpression of the pro-invasive hMENAΔv6 increases fibronectin production. In primary tumors high hMENA11acorrelates with low stromal fibronectin and a favorable clinical outcome of early node-negative non-small-cell lung cancer patients. These data provide new insights into the roles of hMENA11aand hMENAΔv6 in the druggable β1 integrin-ECM signaling axis and allow stratification of patient risk, guiding their clinical management.
- Published
- 2018
- Full Text
- View/download PDF
5. The Dilemma of HER2 Double-equivocal Breast Carcinomas
- Author
-
Marchiò, Caterina, Dell’Orto, Patrizia, Annaratone, Laura, Geyer, Felipe C., Venesio, Tiziana, Berrino, Enrico, Verdun di Cantogno, Ludovica, Garofoli, Andrea, Rangel, Nelson, Casorzo, Laura, dell’Aglio, Carmine, Gugliotta, Patrizia, Trisolini, Elena, Beano, Alessandra, Pietribiasi, Francesca, Orlassino, Renzo, Cassoni, Paola, Pich, Achille, Montemurro, Filippo, Mottolese, Marcella, Vincent-Salomon, Anne, Penault-Llorca, Frédérique, Medico, Enzo, Ng, Charlotte K.Y., Viale, Giuseppe, and Sapino, Anna
- Abstract
Supplemental Digital Content is available in the text.The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2013 guidelines for HER2 assessment have increased the number of HER2 equivocal breast carcinomas following in situhybridization reflex testing, that is, HER2 “double equivocal” (equivocal protein expression and equivocal gene copy number). Forty-five double-equivocal carcinomas were subjected to Prosigna analysis. Twenty-seven cases were investigated for the expression of genes found to be differentially expressed between estrogen receptor (ER)-positive/HER2-positive (N=22) and ER-positive/HER2-negative (N=22) control cases. Twenty-nine of the 45 cases were also analyzed by targeted sequencing using a panel of 14 genes. We then explored the pathologic complete response rates in an independent series of double-equivocal carcinoma patients treated with trastuzumab-containing chemotherapy. All cases were ER-positive, with a mean Ki67 of 28%. Double-equivocal carcinomas were predominantly luminal B (76%); 9 cases (20%) were luminal A, and 2 cases (4%) HER2-enriched. The majority (73%) showed a high risk of recurrence by Prosigna, even when the carcinomas were small (<2 cm), node-negative/micrometastatic, and/or grade 2. Double-equivocal carcinomas showed TP53(6/29, 20%), PIK3CA(3/29, 10%), HER2(1/29, 3%), and MAP2K4(1/29, 3%) mutations. Compared with grade-matched ER-positive/HER2-negative breast carcinomas from METABRIC, double-equivocal carcinomas harbored more frequently TP53mutations and less frequently PIK3CAmutations (P<0.05). No significant differences were observed with grade-matched ER-positive/HER2-positive carcinomas. Lower pathologic complete response rates were observed in double-equivocal compared with HER2-positive patients (10% vs. 60%, P=0.009). Double-equivocal carcinomas are preferentially luminal B and show a high risk of recurrence. A subset of these tumors can be labeled as HER2-enriched by transcriptomic analysis. HER2mutations can be identified in HER2 double-equivocal cases.
- Published
- 2018
- Full Text
- View/download PDF
6. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
- Author
-
Manic, Gwenola, Signore, Michele, Sistigu, Antonella, Russo, Giorgio, Corradi, Francesca, Siteni, Silvia, Musella, Martina, Vitale, Sara, De Angelis, Maria Laura, Pallocca, Matteo, Amoreo, Carla Azzurra, Sperati, Francesca, Di Franco, Simone, Barresi, Sabina, Policicchio, Eleonora, De Luca, Gabriele, De Nicola, Francesca, Mottolese, Marcella, Zeuner, Ann, Fanciulli, Maurizio, Stassi, Giorgio, Maugeri-Saccà, Marcello, Baiocchi, Marta, Tartaglia, Marco, Vitale, Ilio, and De Maria, Ruggero
- Abstract
ObjectiveCancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.DesignTo discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents.ResultsThe drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368.ConclusionsLY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RASmutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.
- Published
- 2018
- Full Text
- View/download PDF
7. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy
- Author
-
Ercolani, Cristiana, Di Benedetto, Anna, Terrenato, Irene, Pizzuti, Laura, Di Lauro, Luigi, Sergi, Domenico, Sperati, Francesca, Buglioni, Simonetta, Ramieri, Maria Teresa, Mentuccia, Lucia, Gamucci, Teresa, Perracchio, Letizia, Pescarmona, Edoardo, Mottolese, Marcella, Barba, Maddalena, Vici, Patrizia, De Maria, Ruggero, and Maugeri-Saccà, Marcello
- Abstract
ABSTRACTThe Hippo kinases MST1/2 and LATS1/2 inhibit the oncoproteins TAZ/YAP and regulate T cell function. Hippo kinases also cooperate with the ATR-Chk1 and ATM-Chk2 pathways, central orchestrators of the DNA damage response (DDR). We hypothesized that MST1/2 and LATS1/2 localization differently impacts the efficacy of neoadjuvant therapy (NAT) in breast cancer, being protective when expressed in the cytoplasm of tumor cells and in tumor-infiltrating lymphocytes, whereas representing molecular determinants of chemoresistance when present in the nucleus as a consequence of their cooperation with the DDR. Diagnostic biopsies from 57 HER2-positive and triple-negative breast cancer patients treated with NAT were immunostained for evaluating the expression of phosphorylated MST1/2 (pMST1/2) and LATS1/2 (pLATS1/2) in tumor-infiltrating lymphocytes (TILs) and in cancer cells. TAZ and Chk1 immunostaining was exploited for investigating subcellular compartment-dependent activity of Hippo kinases. Nuclear pMST1/2 (pMST1/2nuc) expression was significantly associated with nuclear expression of Chk1 (p = 0.046), whereas cytoplasmic pMST1/2 (pMST1/2cyt) expression was marginally associated with cytoplasmic TAZ staining (p = 0.053). Patients whose tumors expressed pMST1/2nucwere at increased risk of residual disease after NAT (pCR ypT0/is ypN0: OR 4.91, 95%CI: 1.57–15.30; pCR ypT0 ypN0: OR 3.59, 95%CI 1.14–11.34). Conversely, exclusive cytoplasmic localization of pMST1/2 (pMST1/2cyt)seemed to be a protective factor (pCR ypT0/is ypN0: OR 0.34, 95%CI: 0.11–1.00; pCR ypT0 ypN0: OR 0.31, 95%CI 0.10–0.93). The subcellular localization-dependent significance of pMST1/2 expression suggests their involvement in different molecular networks with opposite impact on NAT efficacy. Larger studies are warranted to confirm these novel findings.
- Published
- 2017
- Full Text
- View/download PDF
8. Cyclin D1 is a major target of miR-206 in cell differentiation and transformation
- Author
-
Alteri, Alessandra, De Vito, Francesca, Nessina, Graziella, Pompili, Monica, Calconi, Attilio, Visca, Paolo, Mottolese, Marcella, Presutti, Carlo, and Grossi, Milena
- Abstract
miR-206, a member of the so-called myomiR family, is largely acknowledged as a specific, positive regulator of skeletal muscle differentiation. A growing body of evidence also suggests a tumor suppressor function for miR-206, as it is frequently downregulated in various types of cancers. In this study, we show that miR-206 directly targets cyclin D1 and contributes to the regulation of CCND1gene expression in both myogenic and non-muscle, transformed cells. We demonstrate that miR-206, either exogenous or endogenous, reduces cyclin D1 levels and proliferation rate in C2C12 cells without promoting differentiation, and that miR-206 knockdown in terminally differentiated C2C12 cells leads to cyclin D1 accumulation in myotubes, indicating that miR-206 might be involved in the maintenance of the post-mitotic state. Targeting of cyclin D1 might also account, at least in part, for the tumor-suppressor activity suggested for miR-206 in previous studies. Accordingly, the analysis of neoplastic and matched normal lung tissues reveals that miR-206 downregulation in lung tumors correlates, in most cases, with higher cyclin D1 levels. Moreover, gain-of-function experiments with cancer-derived cell lines and with in vitro transformed cells indicate that miR-206-mediated cyclin D1 repression is directly coupled to growth inhibition. Altogether, our data highlight a novel activity for miR-206 in skeletal muscle differentiation and identify cyclin D1 as a major target that further strengthens the tumor suppressor function proposed for miR-206.
- Published
- 2013
- Full Text
- View/download PDF
9. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
- Author
-
Fabi, Alessandra, Merola, Roberta, Ferretti, Gianluigi, Di Benedetto, Anna, Antoniani, Barbara, Ercolani, Cristiana, Nisticò, Cecilia, Papaldo, Paola, Ciccarese, Mariangela, Sperduti, Isabella, Vici, Patrizia, Marino, Mirella, Gori, Stefania, Botti, Claudio, Malaguti, Paola, Cognetti, Francesco, and Mottolese, Marcella
- Abstract
Objective:Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor (TKI), associated to capecitabine represents the treatment of choice in HER2-positive metastatic breast cancer (BC) patients in progression after trastuzumab-based therapy. Though lapatinib-based therapy prolongs the time to progression, its efficacy is often limited by the development of drug resistance. It is aimed to evaluate novel biomarkers predictive of lapatinib response, we analyzed EGFR protein and gene status in a series of 50 metastatic HER2-positive BC patients.Methods:Lapatinib was given at 1250 mg/day continuously and capecitabine at 2000 mg/m2/day every 3 weeks. EGFR protein expression and gene copy number (GCN) were assessed by immunohistochemistry and FISH, respectively. Receiver operating curve (ROC) analysis identified the value of > 3.36 EGFR copies/nucleus as the cut-off point able to discriminate responders versus non-responders.Results:A statistical significant correlation between EGFR GCN value > 3.36 and response to lapatinib (p 0.01) was found. Cox regression analysis further supported these findings evidencing that HER2 score 3 and EGFR GCN increase are positive predictor factors of lapatinib response.Conclusions:Though further investigations are needed to confirm these findings, EGFR GCN could be a suitable screening to identify the subset of BC patients particularly responsive to the dual TKI lapatinib.
- Published
- 2013
- Full Text
- View/download PDF
10. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
- Author
-
Novelli, Flavia, Milella, Michele, Melucci, Elisa, Di Benedetto, Anna, Sperduti, Isabella, Perrone-Donnorso, Raffaele, Perracchio, Letizia, Venturo, Irene, Nisticò, Cecilia, Fabi, Alessandra, Buglioni, Simonetta, Natali, Pier, and Mottolese, Marcella
- Abstract
Estrogen receptor-alpha (ER-α) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-β) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-β distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN). We conducted an observational prospective study using immunohistochemistry to evaluate ER-β expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-β on disease-free survival in the 728 patients with complete follow-up data. ER-β evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-β and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-β positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-α/PgR/Bcl2-tumors. Kaplan-Meier curves and Cox regression analysis identified ER-β as a significant discriminating factor for disease-free survival both in the node-negative LA (P= 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P= 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse. Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-β positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-β isophorms.
- Published
- 2008
- Full Text
- View/download PDF
11. HER-2-positive metastatic breast cancer: trastuzumab and beyond
- Author
-
Metro, Giulio, Mottolese, Marcella, and Fabi, Alessandra
- Abstract
Background: The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. Objectives: The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. Methods: A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. Results: Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective ‘chemotherapy-free’ combination for trastuzumab-refractory patients.
- Published
- 2008
- Full Text
- View/download PDF
12. New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinomaPresented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5–8, 2004.: A pooled analysis of the randomized trials
- Author
-
Carlini, Paolo, Bria, Emilio, Giannarelli, Diana, Ferretti, Gianluigi, Felici, Alessandra, Papaldo, Paola, Fabi, Alessandra, Nisticò, Cecilia, Di Cosimo, Serena, Ruggeri, Enzo Maria, Milella, Michele, Mottolese, Marcella, Terzoli, Edmondo, and Cognetti, Francesco
- Abstract
New aromatase inhibitors (AI) (second‐generation: formestane and fadrozole; third‐generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC). They have resulted in better survival compared with megestrol acetate (MEG) in a number of studies. The authors performed a pooled analysis including all the Phase III trials published between 1996 and 2004 evaluating the AIs approved or not by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medical Products (EMEA) as second‐line endocrine therapy (ET) for patients with MBC.The overall response rate (ORR) and time to disease progression (TTP) were considered the primary end points, whereas toxicity was regarded as a secondary objective. Relative risk, 95% confidence interval, and heterogeneity were derived using 2 methods.No significant differences in ORR and TTP were noted in the entire group of 9 trials comparing AI with MEG (3908 patients) and in the 6 trials comparing nonsteroidal AI and MEG (2415 patients). AI yielded significantly more hot flashes than MEG (P = 0.004) but caused significantly less toxicity than MEG in weight gain (P = 0.001), dyspnea (P = 0.008), and peripheral edema (P = 0.03). Significant heterogeneity for nausea, weight gain, dyspnea, and peripheral edema was registered. When steroidal AIs were excluded from the toxicity analysis, nausea maintained its strongly significant heterogeneity (P = 0.0002), whereas weight gain, dyspnea, and peripheral edema lost their significance.This pooled analysis suggested that AIs in second‐line ET for patients with MBC do not seem to add any significant benefit to MEG in terms of ORR and TTP. With regard to toxicity, the findings in the current study showed that weight gain, dyspnea, and peripheral edema are more frequent with the use of MEG, whereas hot flashes were more represented using AI. Cancer 2005. © 2005 American Cancer Society.
- Published
- 2005
- Full Text
- View/download PDF
13. Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity
- Author
-
Zaffaroni, Nadia, Della Porta, Chiara, Villa, Raffaella, Botti, Claudio, Buglioni, Simonetta, Mottolese, Marcella, and Grazia Daidone, Maria
- Abstract
Telomerase activity was determined in 15 breast cancers, 24 benign breast lesions, and 36 breast tissues adjacent to benign or malignant tumours. A positive TRAP (telomeric repeat amplification protocol) signal was detected in 67% of carcinomas and 29% of benign tumours. In five of ten cases, non‐invaded breast tissues adjacent to telomerase‐positive carcinomas also displayed telomerase activity. Conversely, in peritumoural specimens adjacent to benign lesions, telomerase activity was never detected. To investigate the regulatory mechanisms of telomerase activity in breast tissues, the expression of telomerase subunits was assessed, as well as the presence of alternatively spliced variants of human telomerase reverse transcriptase (hTERT). The presence of the hTERT full‐length transcript appeared necessary for telomerase activity in breast carcinomas. Specifically, all telomerase‐positive carcinomas expressed the hTERT full‐length message, together with different combinations of alternatively spliced variants, whereas in telomerase‐negative cancers, the hTERT full‐length transcript was not detectable, or its abundance was markedly lower than that of alternatively spliced variants. Results obtained in benign tumours and normal tissues surrounding carcinomas instead showed that the presence of hTERT full‐length transcript was not sufficient to determine telomerase activity. These findings suggest that in non‐neoplastic tissues there are other mechanisms that suppress telomerase activity downstream from hTERT transcription and mRNA splicing and that such mechanisms have been lost during neoplastic transformation. Copyright © 2002 John Wiley & Sons, Ltd.
- Published
- 2002
- Full Text
- View/download PDF
14. Molecular Stability of DNA Typing Short Tandem Repeats in the Mammary Tree of Patients with Breast Cancer
- Author
-
Orlandi, Francesca, Barucca, Alessandra, Biagini, Guido, Pasqui, Gastone, Mottolese, Marcella, Botti, Claudio, Bracalenti, Carla, Cardarelli, Marco Andrea, Concetti, Antonio, and Venanzi, Franco Maria
- Abstract
Archival pathologic specimens are a rich source for the studies of hereditary diseases, cancer genetics, and identification cases in forensic science. In this study, the intraindividual consistency of eight identifying microsatellite polymorphisms (i.e., HMTH01, vWFA31, F13A, MITMH26, FES-FPS, CD4, TPOX, CSF1PO)in a cohort of 40 patients with invasive breast carcinoma were analyzed. Nests of cancer and adjacent morphologically normal ductal–lobular structures (TDLUs) were microdissected as discrete regions from hematoxylin-eosin–stained slides. As controls for each case, DNA templates were prepared from TDLUs located in nontumor quadrants and from unaffected breast skin. Over 1,400 carefully controlled PCR reactions were reviewed, and no evidence was found for microsatellite mismatches among intraindividual cancer and control DNAs. The negative results, supported by validation experiments, strongly argue that alterations of simple repeats are rare somatic events during the onset and progression of breast cancer.
- Published
- 2002
15. c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer
- Author
-
Biroccio, Annamaria, Benassi, Barbara, D’Agnano, Igea, D’Angelo, Carmen, Buglioni, Simonetta, Mottolese, Marcella, Ricciotti, Andrea, Citro, Gennaro, Cosimelli, Maurizio, Ramsay, Robert G., Calabretta, Bruno, and Zupi, Gabriella
- Abstract
The aim of this study was twofold: to assess the relationship between c-Myb and Bcl-x expression and to evaluate the prognostic significance of their expression in colorectal carcinoma (CRC) patients. Analysis of tumors from 91 CRC patients for expression of c-Myb and Bcl-x revealed a significant relationship between these two proteins. Kaplan-Meier’s analysis showed an increased risk of relapse and death in patients whose tumor specimens displayed high c-Myb levels and Bcl-x positivity. Similar results were also observed excluding Dukes’ D patients. Molecular analysis using three c-Myb-overexpressing LoVo clones indicated that c-Myb overexpression was accompanied by up-regulation of Bcl-xLprotein and mRNA. Tumors originating from these clones injected in nude mice were significantly larger than those formed in mice injected with parental or vector-transfected LoVo cells. Moreover, tumors derived from parental and control vector-transfected but not from c-Myb-overexpressing LoVo cells showed high frequency of apoptotic cells. These results provide direct evidence of an association between c-Myb and Bcl-x expression and suggest that expression of both molecules might be a useful prognostic marker in CRC.
- Published
- 2001
- Full Text
- View/download PDF
16. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
- Author
-
Mottolese, Marcella, Benevolo, Maria, Del Monte, Girolamo, Buglioni, Simonetta, Papaldo, Paola, Nisticò, Cecilia, Di Filippo, Franco, Vasselli, Stefania, Vici, Patrizia, and Botti, Claudio
- Abstract
Abstract: Purpose: Adjuvant therapy has become an integral component of the management of primary high-risk breast cancer patients. However, a considerable fraction of women receive no benefit from this treatment. This study investigates whether a number of biopathological factors can influence the outcome of patients submitted to adjuvant chemotherapy involving the use of high-dose epirubicin and cyclophosphamide. Methods: One hundred and fifty-seven primary breast cancer patients, considered at high risk according to the St. Gallen Meeting Consensus Conference, were evaluated immunohistochemically for estrogen, progesterone receptors, p53, bcl-2, HER-2/neu, and Ki-67, of which the results were correlated with patient outcome. Results: Results obtained demonstrated that p53 is a significant predictor of disease-free survival (DFS P < 0.0001) and overall survival (OS P=0.0002) both in ductal and lobular carcinomas, whereas bcl-2 expression seems to be of prognostic value only in lobular carcinomas (DFS P=0.01; OS P=0.02). Conclusions: This data indicates that in high-risk breast cancer patients the immunohistochemical evaluation of p53 and bcl-2 may be of clinical value in distinguishing different responses to adjuvant anthracycline-based chemotherapy.
- Published
- 2000
- Full Text
- View/download PDF
17. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity
- Author
-
Morini, Monica, Mottolese, Marcella, Ferrari, Nicoletta, Ghiorzo, Federica, Buglioni, Simonetta, Mortarini, Roberta, Noonan, Douglas M., Natali, Pier Giorgio, and Albini, Adriana
- Abstract
The α3β1 integrin is elevated in several types of metastatic tumor and has been associated with increased migration and invasion. Our analysis of a series of mammary carcinomas of different histotypes and their corresponding metastases demonstrated significantly increased expression of α3β1 in the tumor metastases. We therefore studied α3β1 expression of several human breast carcinoma cell lines and its association with the invasive phenotype. The MDA-MB-231 cell line expressed high levels of the β1, α2, α3, α5, and α6 integrin subunits along with moderate levels of the αvβ3 integrin. This line was highly migratory and the most invasive using a chemo-invasion assay. In contrast, the other lines tested, MDA-MB-145, MCF-7, and SK-BR-3, showed lower migratory and invasive activity and reduced α3 integrin subunit expression. Metalloproteases capable of degrading collagen IV are necessary for the invasive process. RT-PCR showed that MDA-MB-231 cells expressed MMP-9, but not MMP-2, gelatinase/collagenase IV. Gelatin zymography demonstrated that invading MDA-MB-231 cells released high levels of MMP-9 gelatinase activity. A direct role for this gelatinase in MDA-MB-231 cell invasion was confirmed by inhibition of invasion using the metalloprotease inhibitorBatimastat. Treatment of MDA-MB-231 cells with a function-blocking anti-α3 antibody strongly inhibited migration and invasion. This correlated with a marked reduction in MMP-9 activity produced by MDA-MB-231 cells, suggesting a role for α3β1 ligand binding in cell signaling and regulation of extracellular matrix degradation. Int. J. Cancer 87:336342, 2000. © 2000 Wiley-Liss, Inc.
- Published
- 2000
- Full Text
- View/download PDF
18. Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study
- Author
-
Botti, Claudio, MD, Pescatore, Barbara, PhD, Mottolese, Marcella, PhD, Sciarretta, Francesco, MD, Greco, Claudia, PhD, Filippo, Franco Di, MD, Gandolfo, Giuseppe Maria, MD, Cavaliere, Francesco, MD, Bovani, Roberta, MS, Varanese, Antonio, MD, and Cianciulli, Anna Maria, PhD
- Abstract
Background: Characterization of the biopathologic events underlying the early steps of breast carcinogenesis may have a dramatic impact on reducing breast cancer mortality. Genes involved in breast tumorigenesis are localized on chromosomes 1 and 17, and numeric aberrations of these chromosomes have been correlated with breast cancer tumorigenesis and progression. According to the field cancerization hypothesis, specific chromosome aberrations may be present in breast cancer and in normal-appearing adjacent tissue. The latter changes reflect the genomic damage that follows longterm carcinogenic exposure and precede the morphologically detectable neoplastic transformation. We hypothesize that detection of these aberrations in benign breast epithelium may provide a tool for molecular risk assessment. Study Design: Using fluorescence in situ hybridization with centromere-specific probes, we determined the status of chromosomes 1 and 17 in fresh imprints of 28 samples of primary tumors and 54 samples of their surrounding uninvolved parenchyma taken from patients undergoing operations for breast carcinoma. Ten contralateral breast biopsy specimens collected from patients with previous breast carcinoma were also evaluated as a surrogate of a high-risk group to rule out the hypothesis that chromosomal aneusomy in tumor-adjacent tissue could be related to a paracrine effect of the primary tumor. Ten samples of benign breast tissue taken from patients at low risk were used as controls to define tolerance limits for aneusomy definition. Results: Using threshold values of 40% of signal loss and 13% of signal gain to define chromosome aneusomy (ie, mean + 3 SDs of the control group signals), we found the following: 1) almost all primary breast tumors were aneusomic for chromosomes 1 and 17; 2) primary breast tumor and adjacent uninvolved parenchyma shared the same pattern of chromosomes 1 and 17 aneusomy in 66.7% of patients; and 3) chromosomes 1 and 17 aneusomies in contralateral benign breast samples from high-risk patients were not different from those in primary breast tumor or adjacent tissue samples. Conclusions: These results suggest that chromosomes 1 and 17 aneusomy may represent an intermediate biomarker of breast tumorigenesis potentially useful to detect patients at high risk of breast carcinoma who may benefit from preventive interventions.
- Published
- 2000
- Full Text
- View/download PDF
19. Bcl‐2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivoangiogenesis in a breast carcinoma line
- Author
-
Biroccio, Annamaria, Candiloro, Antonio, Mottolese, Marcella, Sapora, Orazio, Albini, Adriana, Zupi, Gabriella, and Del Bufalo, Donatella
- Abstract
We have previously demonstrated that bcl‐2 overexpression enhances the metastatic potential of the MCF7 ADR human breast cancer cell line resistant to adriamycin by inducing metastasis‐associated properties. To further elucidate the relationship between bcl‐2 expression and the metastatic potential of the MCF7 ADR line, we evaluated whether bcl‐2 could be also involved in the modulation of the angiogenic phenotype. Four bcl‐2‐overex‐pressing clones, a control transfectant clone, and the MCF7 ADR parental line were used for in vitroand in vivoexperiments. Bcl‐2 overexpression enhanced the synthesis of the hypoxia‐stimulated VEGF protein and mRNA. Northern blot analysis demonstrated an increased VEGF mRNA expression in bcl‐2‐overex‐pressing clones, and reverse transcription‐polymer‐ase chain reaction showed higher levels of the VEGF121and VEGF165mRNA isoforms, which are the most active in eliciting angiogenesis. When incorporated into matrigel, supernatants of bcl‐2‐trans‐fected cells cultured under hypoxic conditions induced an increased angiogenic response in C57BL/6 mice compared with that of control clone. Tumors from bcl‐2 transfectants demonstrated increased VEGF expression and neovascularization as compared to the parental line, whereas the apoptosis in in vivoxenografts was similar in control and bcl‐2 transfectants. The effect of bcl‐2 on angiogenesis was not mediated by p53 protein. These results demonstrate that bcl‐2 and hypoxia can act synergis‐tically to modulate VEGF expression and the in vivoangiogenic response in the MCF7 ADR line.—Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zupi, G., Del Bufalo, D. Bcl‐2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivoangiogenesis in a breast carcinoma line. FASEB J.14, 652–660 (2000)
- Published
- 2000
- Full Text
- View/download PDF
20. Prognostic relevance of altered Fas (CD95)-system in human breast cancer
- Author
-
Mottolese, Marcella, Buglioni, Simonetta, Bracalenti, Carla, Cardarelli, Marco Andrea, Ciabocco, Luciana, Giannarelli, Diana, Botti, Claudio, Natali, Pier Giorgio, Concetti, Antonio, and Venanzi, Franco Maria
- Abstract
The Fas ligand (FasL) and its receptor Fas (APO-1 or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin-fixed tissues showed that 91.1% of benign lesions expressed Fas, which was present in only 56.7% of malignant tumors. On the other hand, FasL was found positive in 22.2% of benign neoplasms and up-regulated in in situ as well as invasive carcinomas (53.9%). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node-negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease-free survival than those with Fas-negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. Int. J. Cancer (Pred. Oncol.) 89:127132, 2000. © 2000 Wiley-Liss, Inc.
- Published
- 2000
- Full Text
- View/download PDF
21. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2
- Author
-
Buglioni, Simonetta, D'Agnano, Igea, Cosimelli, Maurizio, Vasselli, Stefania, D'Angelo, Carmen, Tedesco, Manfredo, Zupi, Gabriella, and Mottolese, Marcella
- Abstract
About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio-pathological markers, predictive of tumour aggressiveness, may offer a more rational approach to planning adjuvant therapy. To this end, we analysed the correlation between p53 accumulation, Bcl-2 expression, DNA ploidy, cell proliferation and conventional clinico-pathological parameters by testing the prognostic significance of these variables in a series of 171 colorectal carcinoma patients with long-term follow-up. The relationships among the various bio-pathological parameters, analysed by multiple correspondence analysis, showed 2 different clinico-biological profiles. The first, characterised by p53 negativity, Bcl-2 positivity, diploidy, low percentage of cells in S-phase (%S-phase), a low Ki-67 score, is associated with Dukes' A-B stage, well differentiated tumours and lack of relapse. The second, defined by p53 positivity, Bcl-2 negativity, aneuploidy, high %S-phase and elevated Ki-67 score, correlates with Dukes' C-D stage, poorly differentiated tumours and presence of relapse. When these parameters were examined according to Kaplan-Meier's method, significantly shorter disease-free (DFS) and overall survival (OS) were also observed in patients bearing p53 positive and Bcl-2 negative tumours, in Dukes' B stage. In multivariate analysis, p53 accumulation and Bcl-2 expression emerged as independent predictors of a worse and better clinical outcome, respectively. Our results indicate that, in colorectal adenocarcinomas, a biological profile, based on the combined evaluation of p53 and Bcl-2, may be useful for identifying high risk patients to be enrolled in an adjuvant setting, mainly in an early stage of the disease. Int. J. Cancer (Pred. Oncol.) 84:545552, 1999. © 1999 Wiley-Liss, Inc.
- Published
- 1999
- Full Text
- View/download PDF
22. Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients
- Author
-
Nisticò, Paola, Mottolese, Marcella, Cascioli, Simona, Benevolo, Maria, Bello, Duilia Del, Modugno, Francesca Di, Rubiu, Oriana, Gentile, Francesco Paolo, Botti, Claudio, Venturo, Irene, and Natali, Pier Giorgio
- Abstract
Overexpression of gp185erbB-2 has been associated with reduced survival in breast-cancer patients. Our earlier results, now confirmed in a larger cohort of patients (798), evidenced that the HLA-A2 allele may participate in the modulation of the erbB-2 tumor phenotype in vivo. In the present study, we evaluated other clinico-biopathologic parameters possibly involved in the host immune response against erbB-2. Localization of the CD3+ T-cell infiltrate was taken into consideration in 705 primary breast tumors, and expression of HLA-class-I and HLA-A2 antigens was evaluated in a subgroup of 170 frozen primary tumors of HLA-A2-positive patients. The presence or the absence of HLA-class-I and HLA-A2 antigens in primary tumors did not correlate with erbB-2 expression. However, HLA-A2-positive tumors preferentially showed intratumoral lymphocyte localization, whereas the lesions displaying undetectable HLA-class-I expression showed peritumoral CD3+ T-cell localization. Taking into account erbB-2 immunoreactivity, we found that the relationship between HLA-A2 expression and intratumoral CD3+ T-lymphocyte localization is significant only in the erbB-2 negative subset, whereas the relationship between lack of HLA-class-I expression and peritumoral CD3+ T-lymphocyte localization is significant only in the erbB-2-positive subset. These data provide novel in vivo evidence of the possible contribution of the host immune system to control of erbB-2 oncogene overexpression in breast cancer. Int. J. Cancer (Pred. Oncol.) 84:598603, 1999. © 1999 Wiley-Liss, Inc.
- Published
- 1999
- Full Text
- View/download PDF
23. Use of Protein a Hearing Staphylococcus Aureus in Enzyme Immunoassay (EIA)
- Author
-
Mottolese, Marcella, Lacona, Angela, and Natali, Prer Giorgio
- Abstract
Bovine serum albumin labeled with alkaline phosphatase and antibody have been employed as a model to determine if the use of Protein A bearing Staphylococcus aureus Cowan I strain (SACl) bacteria could be extended to enzyme immunoassay (EIA). SACl do not activate "per se" the enzyme substrate and bind aspecifically minimum amount of enzyme labeled antigen. Experimental conditions are described for the use of SACI both in macro and micro EIA assay which allows the processing of numerous samples with minimum hand ling. The sensitivity of the EIA is comparable with radioassay (EIA 2ng-RIA 4ng) which uses SACI in place of second antibody. The inhibition test can be performed in 4 hours time. These results suggest that the stability of SACl when combined with that of enzyme labeled antigens can widen the use of EIA, both for investigative and clinical studies.
- Published
- 1980
- Full Text
- View/download PDF
24. High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen-specific vaccination strategies
- Author
-
Dalerba, Piero, Ricci, Axel, Russo, Vincenzo, Rigatti, Donata, Nicotra, Maria Rita, Mottolese, Marcella, Bordignon, Claudio, Natali, Pier Giorgio, and Traversari, Catia
- Abstract
Human melanoma cells express several antigens which are recognized by autologous and specific CTL clones in association with HLA-class-I molecules. Many of these antigens represent suitable targets for tumor immunotherapy, since their expression in human melanoma cells is common and highly specific. In order to achieve real clinical success with therapeutic vaccination strategies, one important requirement is the expression of the target antigen by all the tumor lesions of a patient. We have studied this issue by assessing, through an RT-PCR approach, the expression of MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE-1/2, Tyrosinase and Melan-A/MART-1 genes in 17 clusters of simultaneous in-transit or regional lymph-node metastases collected from 15 stage-III and 1 stage-IV (AJCC/UICC pTNM system) melanoma patients. In 14 out of 17 clusters of simultaneous metastatic lesions (82%), the homogeneity in the pattern of gene expression within the cluster was complete. Heterogeneity within the same cluster was observed in only 3 out of 17 clusters (18%) and represented only minor features. Our data reveal that, in AJCC-stage-III melanoma patients, different but simultaneous metastatic lesions express the same pattern of antigen-coding genes. These observations have 2 main clinical implications: (i) the antigenic characterization of one single and easily accessible lesion allows identification of optimal targets for an active antigen-specific immunotherapy treatment; (ii) almost all the metastatic lesions are expected to be hit by the immune response eventually induced against the tumor antigen. Moreover, these data suggest that active specific immunotherapy directed against MAGE-1, MAGE-3, BAGE, GAGE-1/2, Melan-A/MART-1 and Tyrosinase antigens could be exploited as an adjuvant treatment to surgery in high-risk AJCC-stage-III-melanoma patients. Int. J. Cancer 77:200204, 1998.© 1998 Wiley-Liss, Inc.
- Published
- 1998
- Full Text
- View/download PDF
25. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas
- Author
-
Pietsch, Torsten, Nicotra, Maria Rita, Fraioli, Rocco, Wolf, Helmut Karl, Mottolese, Marcella, and Natali, Pier Giorgio
- Abstract
Increasing experimental evidence indicates that stem-cell factor (SCF) and its cognate receptor c-Kit may participate in the growth control of various solid human malignancies. In the present study, we have extended this analysis to non-small-cell lung carcinomas (NSCLC). The results of an immunohistochemical analysis demonstrated that c-Kit/SCF are expressed by 30%/58% of adenocarcinomas, 15%/37% of squamous-cell carcinomas and by 40%/30% of undifferentiated carcinomas respectively. In 15% of primary and 18% of metastatic tumors, co-expression of the receptor and its ligand was documented. Western-blot assays of tumor extracts demonstrated that both molecules exhibit features of the normal receptor and ligand. Since biologically active SCF is physiologically present in the bloodstream, our data indicate that SCF is available to c-kit-expressing NSCLC cells via autocrine, paracrine or endocrine mechanisms. Thus activation of c-Kit in these tumors may contribute critically to their progression. Int. J. Cancer 75:171175, 1998. © 1998 Wiley-Liss, Inc.
- Published
- 1998
- Full Text
- View/download PDF
26. Noninvasive Monitoring of Ovarian Cancer: Improved Results Using CT with Intraperitoneal Contrast Combined with Immunocytology
- Author
-
Giunta, Salvatore, Venturo, Irene, Mottolese, Marcella, Salzano, Marco, Diotallevi, Fabio, Squillaci, Saverio, Bigotti, Aldo, Curcio, Corrado Gallo, Atlante, Giuseppe, and Natali, Pier Giorgio
- Abstract
The purpose of this study was to evaluate whether CT with intraperitoneal contrast (ipc/CT) in combination with immunocytochemical (ICC) tests could improve the diagnostic accuracy over conventional methods in the follow-up of ovarian carcinoma. Forty-five clinically disease-free ovarian cancer patients eligible for a second-look laparotomy were given an intraperitoneal infusion of positive contrast material followed by pelvic and abdominal CT. After the radiographic examination, the contrast fluid was collected by paracentesis and processed for morphological as well as for immunocytochemical analysis employing a panel of monoclonal antibodies identifying distinct ovarian tumor-associated antigens. While ipc/CT correctly detected the presence of peritoneal recurrences in 22 of 45 (49%) patients, the immunocytochemical tests demonstrated the presence of otherwise undiagnosed microscopic disease in an additional 8 patients (18%). Our results demonstrate that the combination of radiological and immunological methods may represent a more accurate, noninvasive means of monitoring ovarian cancer, thus reducing the need for a second-look laparotomy.
- Published
- 1994
- Full Text
- View/download PDF
27. Use of monoclonal antibodies in solid tumors diagnosis-the endometrial carcinoma
- Author
-
Bartolazzi, Armando, Mottolese, Marcella, Vocaturo, Amina, Vocaturo, Giuseppe, Bigotti, Aldo, Prat, Maria, and Giorgio Natali, Giuseppe Atlante e Pier
- Published
- 1991
- Full Text
- View/download PDF
28. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment
- Author
-
Buglioni, Simonetta, Vici, Patrizia, Sergi, Domenico, Pizzuti, Laura, Di Lauro, Luigi, Antoniani, Barbara, Sperati, Francesca, Terrenato, Irene, Carosi, Mariantonia, Gamucci, Teresa, Vincenzoni, Cristina, Mariani, Luciano, Vizza, Enrico, Venuti, Aldo, Sanguineti, Giuseppe, Gadducci, Angiolo, Barba, Maddalena, Natoli, Clara, Vitale, Ilio, Mottolese, Marcella, De Maria, Ruggero, and Maugeri-Saccà, Marcello
- Abstract
ABSTRACTHippo is a tumor-suppressor pathway that negatively regulates the oncoproteins TAZ and YAP. Moreover, Hippo affects the biology of a variety of non-neoplastic cells in the tumor microenvironment, even including immune cells. We herein assessed the predictive role of TAZ and YAP, assessed by immunohistochemistry, in 50 cervical cancer patients prevalently treated with neoadjuvant chemotherapy. Tumors were classified as positive or negative according to the percentage of tumor-expressing cells and cellular localization. TAZ/YAP were also evaluated in non-neoplastic cells, namely endothelial cells, non-lymphocytic stromal cells and tumor-infiltrating lymphocytes (TILs). TAZ expression in cancer cells (TAZpos) was associated with a reduced pathological complete response (pCR) rate (p= 0.041). Conversely, the expression of TAZ and YAP in TILs (TAZTIL+and YAPTIL+) seemed to be associated with increased pCRs (p= 0.083 and p= 0.018, respectively). When testing the predictive significance of the concomitant expression of TAZ in cancer cells and its absence in TILs (TAZpos/TAZTIL-), patients with TAZpos/TAZTIL-showed lower pCR rate (p= 0.001), as confirmed in multivariate analysis (TAZpos/TAZTIL-: OR 8.67, 95% CI: 2.31–32.52, p= 0.001). Sensitivity analysis carried out in the 41 patients treated with neoadjuvant chemotherapy yielded comparable results (TAZpos/TAZTIL-: OR 11.0, 95% CI: 2.42–49.91, p= 0.002). Internal validation carried out with two different procedures confirmed the robustness of this model. Overall, we found evidence on the association between TAZ expression in cervical cancer cells and reduced pCR rate. Conversely, the expression of the Hippo transducers in TILs may predict increased treatment efficacy, possibly mirroring the activation of a non-canonical Hippo/MST pathway necessary for T-cells activation and survival.
- Published
- 2016
- Full Text
- View/download PDF
29. HER2 Status Determination: Analyzing the Problems to Find the Solutions
- Author
-
Terrenato, Irene, Pennacchia, Ilaria, Buglioni, Simonetta, Mottolese, Marcella, Arena, Vincenzo, and Bombardiere., Sergio Gonzalez
- Published
- 2015
- Full Text
- View/download PDF
30. EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors
- Author
-
Avraham, Roi, Sas-Chen, Aldema, Manor, Ohad, Steinfeld, Israel, Shalgi, Reut, Tarcic, Gabi, Bossel, Noa, Zeisel, Amit, Amit, Ido, Zwang, Yaara, Enerly, Espen, Russnes, Hege G., Biagioni, Francesca, Mottolese, Marcella, Strano, Sabrina, Blandino, Giovanni, Børresen-Dale, Anne-Lise, Pilpel, Yitzhak, Yakhini, Zohar, Segal, Eran, and Yarden, Yosef
- Abstract
Some cancers showed decreased abundance of a subset of EGF-regulated microRNAs, which allows the production of oncogenic transcription factors.
- Published
- 2010
- Full Text
- View/download PDF
31. Gene Copy Number Variation in Male Breast Cancer by aCGH
- Author
-
Tommasi, Stefania, Mangia, Anita, Iannelli, Giuseppina, Chiarappa, Patrizia, Rossi, Elena, Ottini, Laura, Mottolese, Marcella, Zoli, Wainer, Zuffardi, Orsetta, and Paradiso, Angelo
- Abstract
Background: Male breast cancer (MBC) is a rare disease and little is known about its etiopathogenesis. Array comparative genomic hybridization (aCGH) provides a method to quantitatively measure the changes of DNA copy number and to map them directly onto the complete linear genome sequences. The aim of this study was to investigate DNA imbalances by aCGH and compare them with a female breast cancer dataset.Methods: We used Agilent Human Genome CGH Microarray Kit 44B and 44K to compare genomic alterations in 25 male breast cancer tissues studied at NCC of Bari and 16 female breast cancer deposited with the Gene Expression Omnibus (GSE12659). Data analysis was performed with Nexus Copy Number 5.0 software.Results: All the 25 male and 16 female breast cancer samples displayed some chromosomal instability (110.93 alterations per patient in female, 69 in male). However, male samples presented a lower frequency of genetic alterations both in terms of loss and gains.Conclusion: aCGH is an effective tool for analysis of cytogenetic aberrations in MBC, which involves different biological processes than female. Male most significant altered regions contained genes involved in cell communication, cell division and immunological response, while female cell–cell junction maintenance, regulation of transcription and neuron development.
- Published
- 2010
- Full Text
- View/download PDF
32. Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients
- Author
-
Stigliano, Vittoria, Assisi, Daniela, Cosimelli, Maurizio, Palmirotta, Raffaele, Giannarelli, Diana, Mottolese, Marcella, Mete, Lupe, Mancini, Raffaello, and Casale, Vincenzo
- Abstract
Background Patients with hereditary non-poliposys colorectal cancer (HNPCC) have better prognosis than sporadic colorectal cancer (CRC). Aim of our retrospective study was to compare the overall survival between sporadic CRC and HNPCC patients.Methods We analyzed a cohort of 40 (25 males and 15 females) HNPCC cases with a hospital consecutive series of 573 (312 males and 261 females) sporadic CRC observed during the period 1970–1993. In 15 HNPCC patients we performed mutational analysis for microsatellite instability. Survival rates were calculated by Kaplan-Meier method and compared with log rank test.Results The median age at diagnosis of the primary CRC was 46.8 years in the HNPCC series versus 61 years in sporadic CRC group. In HNPCC group 85% had a right cancer location, vs. 57% in the sporadic cancer group. In the sporadic cancer group 61.6% were early-stages cancer (Dukes' A and B) vs. 70% in the HNPCC group (p = ns). The crude 5-years cumulative survival after the primary CRC was 94.2% in HNPCC patients vs. 75.3% in sporadic cancer patients (p < 0.0001).Conclusion Our results show that overall survival of colorectal cancer in patients with HNPCC is better than sporadic CRC patients. The different outcome probably relates to the specific tumorigenesis involving DNA mismatch repair dysfunction.
- Published
- 2008
- Full Text
- View/download PDF
33. Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions
- Author
-
Greco, Claudia, Vona, Rosa, Cosimelli, Maurizio, Matarrese, Paola, Straface, Elisabetta, Scordati, Patrizia, Giannarelli, Diana, Casale, Vincenzo, Assisi, Daniela, Mottolese, Marcella, Moles, Anna, and Malorni, Walter
- Abstract
Galectins are a family of beta-galactoside binding molecules involved in cell–extracellular matrix adhesion processes. Specifically, Galectin-3 (Gal-3), one of the members of this family of molecules plays a role in cell adhesion processes as well as in cell survival or apoptosis. Gal-3 was also hypothesized to represent a useful tool in tumor characterization, for example, in thyroid tumors. We report herein the results obtained by evaluating Gal-3 expression of colon cells from human adenomas and adenocarcinomas with two different methodologies: immunohistochemistry and flow cytometry of living dispersed cells. We found that (1) the expression of Gal-3 was significantly increased on the surface of cells from adenomas with respect to normal mucosa from the same patient; (2) Gal-3 ligand, 90k molecule, was increased in the blood plasma from patients with both adenomatous and adenocarcinomatous lesions; and (3) Gal-3 overexpression was not related with the presence of K-ras mutation. Altogether these results clearly indicate that the evaluation of Gal-3 expression (and of its ligand, 90k) can be of interest in the characterization of nonmalignant and malignant colon cancers.
- Published
- 2004
- Full Text
- View/download PDF
34. The oxidative damage of the mucosa is increased in Helicobacter pylori-positive atrophic gastritis and decreases after eradication
- Author
-
Iacopini, Federico, Consolazio, Adriana, Marcheggiano, Adriana, Mottolese, Marcella, Brenna, Alessia, Solda’, Elena, Iannoni, Carlo, Pica, Roberta, Paoluzi, Omero Alessandro, and Paoluzi, Paolo
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.